GSK Q2 Preview: Focus On PARP And HIV Pill
Analysts are waiting to see how the drugs giant intends to drive growth for new products, with a particular interest in the prospects for the PARP inhibitor Zejula and the single-pill, two-drug HIV therapy Dovato.
You may also be interested in...
A Switch To ViiV's Two-Drug Dovato Keeps HIV Suppressed
Top-line results from the Phase III TANGO study suggests that switching to ViiV’s two-drug Dovato from a three-drug regimen does not affect the efficacy of treatment.
GSK Revamps Sales Reps Incentives To Be Competitive In Cancer
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.
Generic Advair: Finally Approved, A Long Time Coming
Mylan's generic version of GlaxoSmithKline's blockbuster asthma drug was approved by the US FDA Jan. 30. Scrip's timeline tracks how the commercial value of the drug for GSK has greatly declined from its peak in 2013.